ClinicalTrials.Veeva

Menu

Effect of Various Treatment Modalities on Dendritic Vial Ulcer

S

Sohag University

Status

Enrolling

Conditions

Corneal Ulcer

Treatments

Drug: Sodium Hyaluronate
Drug: Acyclovir
Drug: Tobramycin
Drug: Fluorometholone

Study type

Observational

Funder types

Other

Identifiers

NCT05313828
soh-med-22-02-28

Details and patient eligibility

About

Eye infection is a prevalent problem in primary care and remains a crucial healthcare concern. According to the American Academy of Ophthalmology (AAO), herpes simplex virus (HSV) keratitis (HSK) is the leading cause of infectious blindness worldwide . HSK is defined as a corneal inflammatory condition caused by the HSV infection . The global incidence of herpetic keratitis is estimated at 1.5 million per year, resulting in 40,000 new cases of severe visual impairment associated with corneal scarring and opacification . HSV type I (HSV-1) is by far the most predominant causative pathogen of eye infections]. HSV-1 is also known for causing orolabial herpes, HSV folliculitis, herpes gladiatorum, herpetic whitlow, and eczema herpeticum . HSV can be transferred to the eye by touching an active lesion and then the eye. The National Health and Nutrition Evaluation revealed a seroprevalence of HSV-1 in 53.9% of 14-49 year olds, and 90% of adults 50 years or older , indicating that the majority of the population has been exposed to this virus thus are at risk of developing HSK.

In this study we evaluate the efficacy of different treatment modalities on viral keratitis HSK.

Enrollment

40 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

patients with epithelial viral ulcers

Exclusion criteria

  • patients with stromal keratitis patients with corneal opacity

Trial design

40 participants in 4 patient groups

group 1'
Description:
patients with viral ulcers will receive antiviral medication with antibiotics
Treatment:
Drug: Tobramycin
Drug: Acyclovir
group 2
Description:
patients with viral ulcers will receive antiviral medication, tear substitutes with antibiotics
Treatment:
Drug: Tobramycin
Drug: Acyclovir
Drug: Sodium Hyaluronate
group 3
Description:
patients with viral ulcers will receive antiviral medication, weak steroids(at the same time) with antibiotics
Treatment:
Drug: Fluorometholone
Drug: Tobramycin
Drug: Acyclovir
group 4
Description:
patients with viral ulcers will receive antiviral medication with antibiotics followed by weak steroid after epithelial healing
Treatment:
Drug: Fluorometholone
Drug: Tobramycin
Drug: Acyclovir

Trial contacts and locations

1

Loading...

Central trial contact

Hany Mahmoud

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems